Navigation Links
Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
Date:1/9/2014

OKLAHOMA CITY, Jan. 9, 2014 /PRNewswire/ --  Altheus Therapeutics, Inc., announced that it has completed enrollment for ZA201, a 6-week, double-blind, active-controlled Phase 2 clinical trial of the efficacy and safety of Zoenasa® Rectal Gel in approximately 120 adult patients with left-sided, or distal, ulcerative colitis.  Topline results are expected in to be available in March or early April. 

(Logo:  http://photos.prnewswire.com/prnh/20140109/DA43446LOGO)

"Positive ZA201 results will validate the entire Zoenasa platform, so we are pleased to have achieved this milestone," commented Dennis Schafer, President and CEO of Altheus. "We look forward to gaining alignment on our registration program with the FDA and other Health Authorities as the next step to making Zoenasa available to IBD patients."

Nearly 1.2 million Americans suffer from inflammatory bowel disease. The two most common forms, ulcerative colitis and Crohn's disease, are chronic lifelong conditions which significantly impact quality of life. Front-line treatment for ulcerative colitis is monotherapy with oral or rectal mesalamine.  However, many patients do not achieve symptomatic or endoscopic remission and must escalate to more expensive and risky treatments.   

Zoenasa is a patented, novel combination of two FDA-approved drugs, with well-established efficacy and safety records, that have been shown to act synergistically to improve the signs and symptoms of ulcerative colitis.  In animal models of colitis, Zoenasa resolved inflammation more rapidly and completely than mesalamine (the current front line standard of care). 

Zoenasa Rectal Gel is being investigated for the treatment of left-sided ulcerative colitis, which affects approximately 80% of ulcerative colitis patients.  The U.S. Food and Drug Administration also granted Zoenasa orphan designation for the treatment of pediatric ulcerative colitis.  An oral formulation of Zoenasa is in pre-clinical development.

About ZA201
The ZA201 clinical trial is a 6-week, double-blind, active-controlled Phase 2 study of the efficacy and safety of Zoenasa® Rectal Gel versus mesalamine standard enema therapy in approximately 120 adult patients with left-sided, or distal, ulcerative colitis. http://clinicaltrials.gov/ct2/show/NCT01586533.

About Altheus Therapeutics
Founded in 2007, Altheus Therapeutics, Inc., of Oklahoma City, OK, is a pharmaceutical development company focused on innovative therapies for the treatment of inflammatory bowel disease. http://altheustherapeutics.com.

Contact: Dennis Schafer, CEO
dschafer@altheustherapeutics.com
(405) 319-8180


'/>"/>
SOURCE Altheus Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Flexion Therapeutics Files Registration Statement for Proposed Initial Public Offering
4. G1 Therapeutics to Present at Biotech Showcase 2014
5. Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
6. Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
7. Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market
8. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
9. Dr. Seth Rudnick Joins G1 Therapeutics as Executive Chairman
10. Advinus Therapeutics, a TATA Enterprise, Meets Year 1 Milestone in Drug Discovery Alliance
11. Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 24, 2017   QR Pharma , Inc., ... novel therapies for the treatment of Alzheimer,s, Parkinson,s ... of four world-class key opinion leaders to its ... QR Pharma,s previous roster of impressive advisors in ... support the development of the breakthrough mechanism of ...
(Date:1/24/2017)... , January 24, 2017 The global  active ... 239.8 billion by 2025, based on a new report by Grand View ... is projected to drive the market over the forecast period. Advancements in ... also estimated to boost growth.  Continue Reading ... ...
(Date:1/24/2017)... 2017 INTRODUCTION Injectable drug delivery systems ... with vials to prefilled syringes, auto-injectors, pen injectors ... become preferred devices for parenteral administration of drugs. ... rising strongly over the past several years. A ... this format for delivering drugs. The popularity of ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... Bellus Medical, a leader in medical aesthetics, ... In his new role Dr. Dobke will provide physician oversight for in-house clinical studies ... Head of Plastic Surgery and Associate Professor of Surgery at UC San Diego Health ...
(Date:1/24/2017)... ... January 24, 2017 , ... Providing solutions to critical economic ... the Frank Hawkins Kenan Institute of Private Enterprise at the University ... makers identified concrete solutions at the “What’s Next, America?” conference at the Kenan ...
(Date:1/24/2017)... Rosa, CA (PRWEB) , ... January 24, 2017 , ... ... is good news for everyone and particularly good news for prostate cancer patients: incidents ... the diagnosis. , According to the report the cancer death rate has dropped from ...
(Date:1/24/2017)... ... ... American Family Care (AFC) has opened a new 4,000+ square foot state-of-the-art urgent ... area. The Bedford clinic will be the nineteenth location opened by AFC in Massachusetts ... Dr. Kristina Orio. Adams and Orio also independently own and operate AFC clinics in ...
(Date:1/24/2017)... ... January 24, 2017 , ... TopConsumerReviews.com recently ... relieving premenstrual syndrome, or PMS . , Most women of child-bearing age ... include cramps, constipation, irritability, headaches, fatigue, and other discomfort. For some women, ...
Breaking Medicine News(10 mins):